19.04.2010 12:22:00

Kennedy Wilson Continues Efforts to Acquire Distressed Condos

Stuart Cramer, president of KW Residential Investments, a division of Kennedy Wilson (NYSE:KW), a Beverly Hills-based international real estate investment and services company, today announced that Stephen Jordan has joined the firm as managing director of acquisitions. Jordan will focus on acquiring distressed condominium projects in the western region of the U.S.

Cramer stated, "We’re thrilled to have someone with the depth of residential experience in acquisitions, marketing, construction, development and execution that Stephen has.”

Jordan’s experience includes acquisitions for John Laing Homes, formerly the country’s second largest private homebuilder, and for Pulte Homes/Del Webb, the largest public homebuilder in the U.S.

"I’m very excited about joining Kennedy Wilson,” Jordan commented. "It’s an established company with a strong reputation and is well positioned for growth. The company’s resources and relationships have allowed it to quickly and aggressively execute deals in today’s distressed market.”

Jordan is a graduate of the U.S. Naval Academy with a B.S. in astronautical engineering and an M.B.A. in real estate and finance from the University of California at Irvine. He is a member of the Urban Land Institute.

About Kennedy Wilson

Founded in 1977, Kennedy Wilson is an international real estate investment and services company headquartered in Beverly Hills, CA with 22 offices in the U.S. and Japan. The company offers a comprehensive array of real estate services including property and asset management, brokerage and auction services, and construction and trust management. Through its fund management and separate account businesses, Kennedy Wilson is a strategic investor and manager of real estate investments in the U.S. and Japan. For further information on Kennedy Wilson, please visit www.kennedywilson.com.

Nachrichten zu Novelos Therapeutics IncShsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Novelos Therapeutics IncShsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!